Lucatumumab is a human anti-CD40 monoclonal antibody. Lucatumumab blocks the interaction of CD40 and its ligand CD40L, inhibiting CD40L-mediated proliferation of normal B cells, CLL cells and non-Hodgkin lymphoma cells. Lucatumumab also mediates antibody-dependent cell-mediated cytotoxicity (ADCC).